Soleno Therapeutics, Inc.
SLNO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4 | $4 | $3 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $4 | $3 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 102.2% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.3% | 97.9% | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 42.3% | -8.7% | – | – |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 39.4% | -14.4% | – | – |
| EPS Diluted | 0.47 | -0.093 | -0.95 | -1.27 |
| % Growth | 603.8% | 90.2% | 25.2% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |